Project description
Lysosomal biomarkers for Parkinson’s disease
Lysosomes are essential cellular organelles responsible for degrading and recycling damaged components. Dysfunction of lysosomes has been increasingly linked to neurodegenerative diseases, including Parkinson’s disease (PD), which affects millions of people worldwide. This is evident by mutations in genes involved in lysosomal pathways that affect the clearance of the presynaptic protein alpha-synuclein, whose misfolding and accumulation is one of the hallmarks of PD. With the support of the Marie Skłodowska-Curie Actions programme, the LEGEND project aims to characterise lysosomes in PD carrying lysosome and alpha-synuclein gene mutations. The idea is to improve our understanding of PD, identify lysosomal biomarkers linked to disease progression and pave the way for new treatments targeting lysosomal dysfunction.
Objective
Parkinson's disease (PD) is a progressive neurodegenerative disorder affecting 10 million people worldwide. No curative treatments are currently available, but only symptomatic ones. Emerging evidence highlights lysosomal dysfunction as a key mechanism in PD pathogenesis, with associated mutations in the LRRK2 and SNCA genes, both linked to lysosomal pathways.
This proposal aims to identify common lysosomal biomarkers associated with PD progression. By employing the innovative LysoIP method, which enables precise lysosome isolation, we will analyse lysosomal profiles in two PD mouse models of LRRK2 and alpha-synuclein across different ages. Our objectives include (1) setting up and validating the LysoIP method in wild-type mice, (2) identifying potential lysobiomarkers in PD mouse models, and (3) validating these biomarkers in cellular models of PD.
This project directly aligns with the EU Work Programme under Horizon Europe, which focuses on advancing our understanding of neurodegenerative diseases and accelerating the discovery of disease-modifying therapies. Identifying lysosomal biomarkers will not only improve our understanding of PD mechanisms but also support the development of novel therapeutic approaches targeting lysosomal dysfunction.
Fields of science (EuroSciVoc)
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: The European Science Vocabulary.
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: The European Science Vocabulary.
- natural sciences biological sciences genetics mutation
- medical and health sciences basic medicine neurology parkinson
You need to log in or register to use this function
We are sorry... an unexpected error occurred during execution.
You need to be authenticated. Your session might have expired.
Thank you for your feedback. You will soon receive an email to confirm the submission. If you have selected to be notified about the reporting status, you will also be contacted when the reporting status will change.
Keywords
Project’s keywords as indicated by the project coordinator. Not to be confused with the EuroSciVoc taxonomy (Fields of science)
Project’s keywords as indicated by the project coordinator. Not to be confused with the EuroSciVoc taxonomy (Fields of science)
Programme(s)
Multi-annual funding programmes that define the EU’s priorities for research and innovation.
Multi-annual funding programmes that define the EU’s priorities for research and innovation.
-
HORIZON.1.2 - Marie Skłodowska-Curie Actions (MSCA)
MAIN PROGRAMME
See all projects funded under this programme
Topic(s)
Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.
Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.
Funding Scheme
Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.
Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.
HORIZON-TMA-MSCA-PF-EF - HORIZON TMA MSCA Postdoctoral Fellowships - European Fellowships
See all projects funded under this funding scheme
Call for proposal
Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.
Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.
(opens in new window) HORIZON-MSCA-2024-PF-01
See all projects funded under this callCoordinator
Net EU financial contribution. The sum of money that the participant receives, deducted by the EU contribution to its linked third party. It considers the distribution of the EU financial contribution between direct beneficiaries of the project and other types of participants, like third-party participants.
35122 PADOVA
Italy
The total costs incurred by this organisation to participate in the project, including direct and indirect costs. This amount is a subset of the overall project budget.